PhosphogluSeparate and concurrent use of 2-deoxy-D-glucose and 3-bromopyruvate in pancreatic cancer cells

Oncology Reports

Volumn 29, Issue 1, 2013, Pages 329-334

  Xiao, Huijie ^a   Li, Shasha ^b   Zhang, Dapeng ^b   Liu, Tongjun ^a   Yu, Ming ^b   Wang, Feng ^b,c  

^a JILIN UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

2 Deoxy D glucose; 3 Bromopyruvate; Glycolysis; Hexokinase; Hypoxia inducible factor 1a; Pancreatic cancer

Indexed keywords

ADENOSINE TRIPHOSPHATE; BROMOPYRUVIC ACID; COPPER ZINC SUPEROXIDE DISMUTASE; DEOXYGLUCOSE; FUMARIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PYRUVIC ACID DERIVATIVE; UNCLASSIFIED DRUG; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; FUMARIC ACID DERIVATIVE; PYRUVATE DEHYDROGENASE COMPLEX; SMALL INTERFERING RNA; SUPEROXIDE DISMUTASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CELL POPULATION; CELL STRAIN MIAPACA2; CELL STRAIN PANC 1; CELL VIABILITY; CONTROLLED STUDY; DRUG EXPOSURE; MITOCHONDRION; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; RNA INTERFERENCE; WILD TYPE; CELL HYPOXIA; CELL PROLIFERATION; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GENETICS; HUMAN; METABOLISM; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADENOSINE TRIPHOSPHATE; ANTIMETABOLITES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CELL HYPOXIA; CELL PROLIFERATION; DEOXYGLUCOSE; DRUG SYNERGISM; ENZYME INHIBITORS; FUMARATES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MITOCHONDRIA; PANCREATIC NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PYRUVATE DEHYDROGENASE COMPLEX; PYRUVATES; RNA, SMALL INTERFERING; SUPEROXIDE DISMUTASE; TUMOR CELLS, CULTURED;

EID: 84872868296     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2085     Document Type: Article

References (32)

1. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: 1182-1186, 1971.
2. Koong AC, Mehta VK, Le QT, et al: Pancreatic tumors show high levels of hypoxia. Int J Radiat Oncol Biol Phys 48: 919-922, 2000.
3. Erler JT, Cawthorne CJ, Williams KJ, et al: Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 24: 2875-2889, 2004.
4. Brown JM, Diehn M and Loo BW Jr.: Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys 78: 323-327, 2010.
5. Warburg O: On the origin of cancer cells. Science 123: 309-314, 1956.
6. Zhong H, De Marzo AM, Laughner E, et al: Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59: 5830-5835, 1999.
7. Semenza GL and Wang GL: A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12: 5447-5454, 1992.
8. Salceda S and Caro J: Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272: 22642-22647, 1997.
9. Fukuda R, Hirota K, Fan F, et al: Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem 277: 38205-38211, 2002.
10. Wang F, Li SS, Segersvärd R, et al: Hypoxia inducible factor-1 mediates effects of insulin on pancreatic cancer cells and disturbs host energy homeostasis. Am J Pathol 170: 469-477, 2007.
11. Natsuizaka M, Ozasa M, Darmanin S, et al: Synergistic up-regulation of Hexokinase-2, glucose transporters and angiogenic factors in pancreatic cancer cells by glucose deprivation and hypoxia. Exp Cell Res 313: 3337-3348, 2007.
12. Mathupala SP, Ko YH and Pedersen PL: Hexokinase-2 bound to mitochondria: cancer's stygian link to the 'Warburg Effect' and a pivotal target for effective therapy. Semin Cancer Biol 19: 17-24, 2009.
13. Kirito K, Hu Y and Komatsu N: HIF-1 prevents the overproduction of mitochondrial ROS after cytokine stimulation through induction of PDK-1. Cell Cycle 8: 2844-2849, 2009.
14. Kurtoglu M, Maher JC and Lampidis TJ: Different toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells. Antioxid Redox Signal 9: 1383-1390, 2007.
15. Maher JC, Savaraj N, Priebe W, et al: Differential sensitivity to 2-deoxy-D-glucose between two pancreatic cell lines correlates with GLUT-1 expression. Pancreas 30: e34-e39, 2005.
16. Wangpaichitr M, Savaraj N, Maher J, et al: Intrinsically lower AKT, mTOR and HIF activity correlates with increased sensitivity to 2-deoxy-D-glucose under hypoxia in lung cancer cell lines. Mol Cancer Ther 7: 1506-1513, 2008.
17. Maher JC, Wangpaichitr M, Savaraj N, et al: Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose. Mol Cancer Ther 6: 732-741, 2007.
18. Hernlund E, Ihrlund LS, Khan O, et al: Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int J Cancer 123: 476-483, 2008.
19. Maschek G, Savaraj N, Priebe W, et al: 2-Deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 64: 31-34, 2004.
20. Ko YH, Pedersen PL and Geschwind JF: Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 173: 83-91, 2001.
21. Chen Z, Zhang H, Lu W and Huang P: Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate. Biochim Biophys Acta 1787: 553-560, 2009.
22. Kim JS, Ahn KJ, Kim JA, et al: Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells: ROS-mediated cell death by 3-BrPA. J Bioenerg Biomembr 40: 607-618, 2008.
23. Hulleman E, Kazemier KM, Holleman A, et al: Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 113: 2014-2021, 2009.
24. Ko YH, Smith BL, Wang Y, et al: Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 324: 269-275, 2004.
25. Pereira da Silva AP, El-Bacha T, Kyaw N, et al: Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem J 417: 717-726, 2009.
26. Greijer AE, van der Groep P, Kemming D, et al: Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 206: 291-304, 2005.
27. Indran IR, Tufo G, Pervaiz S and Brenner C: Recent advances in apoptosis, mitochondria and drug resistance in cancer cells. Biochim Biophys Acta 1807: 735-745, 2011.
28. Mangerich A and Bürkle A: How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation. Int J Cancer 128: 251-265, 2011.
29. Koivunen P, Hirsilä M, Remes AM, et al: Inhibition of hypoxia-inducible factor (HIF) hydroxylases by citric acid cycle intermediates: possible links between cell metabolism and stabilization of HIF. J Biol Chem 282: 4524-4532, 2007.
30. Liang HL, Sedlic F, Bosnjak Z and Nilakantan V: SOD1 and MitoTEMPO partially prevent mitochondrial permeability transition pore opening, necrosis, and mitochondrial apoptosis after ATP depletion recovery. Free Radic Biol Med 49: 1550-1560, 2010.
31. Ha HC and Snyder SH: Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci USA 96: 13978-13982, 1999.
32. Qin JZ, Xin H and Nickoloff BJ: 3-Bromopyruvate induces necrotic cell death in sensitive melanoma cell lines. Biochem Biophys Res Commun 396: 495-500, 2010.